Costly ticket, worth entry – why Brazil should be on every orphan drug developer’s radar
• “Cost-Brazil” is the main challenge to accessing the country’s market. Why isn’t that an excuse?
• Why lawsuits is still the only access alternative until Orphan Drugs legislation is approved
• Increasing engagement and pro-activeness of patient groups in Brazil are set to change the access to therapies scenario
• Overcoming quality certification, special jurisdiction and high pricing barriers for orphan drugs commercialization

Devaney Baccarin, President and Chief Executive Officer, BaccarinD/DRS-Oncoprod

World Orphan Drug Congress USA 2014

свернуть